Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | ||
| NCT00062855 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | ||
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | ||
| NCT04401410 | Anti-SARS Cov-2 T Cell Infusions for COVID 19 | ||
| NCT03093350 | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer | ||
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | ||
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma | ||
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors | ||
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | ||
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy | ||
| NCT02108522 | Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT00590083 | Administration of Virus-Specific Cytotoxic T-Lymphocytes | ||
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | ||
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | ||
| NCT00058604 | Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | ||
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | ||
| NCT01953900 | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma | ||
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT00953420 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors | ||
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ||
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | ||
| NCT00048386 | Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy | ||
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | ||
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | ||
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | ||
| NCT01945619 | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) | ||
| NCT00880789 | Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT02475707 | Administration of Donor MultiTAA-Specific T Cells for ALL | ||
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | ||
| NCT00590460 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | ||
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | ||
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | ||
| NCT00368082 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | ||
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene | ||
| NCT03081910 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | ||
| NCT00709033 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | ||
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) | ||
| NCT00040482 | High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells |
